Cleanser, Acne Mask
DeviceA facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
Other names: Light Therapy Mask
NCT Number: NCT03124381
This study will compare two different acne treatment regimens for the treatment of acne. Half of participants will receive a cleanser and a light therapy mask, while half of the participants will receive a cleanser, a light therapy topical gel-cream, and a light therapy mask.
Looking for future studies?
Notify Me12 year–40 year
All sexes
Interventional
Not applicable
Academic Dermatology Associates, Albuquerque, New Mexico, United States
Acne vulgaris is a common chronic skin disease involving blockage and/or inflammation of the hair follicles and their accompany sebaceous glands.
Research has shown the benefits of red and blue light therapy in the treatment of mild to moderate acne, with red and blue light shown to target acne-causing bacteria and have an effect on inflammation reduction.
Light-based therapies have been used successfully to treat dermatological conditions since the early 1900s, with various parts of the electromagnetic spectrum (i.e. ultraviolet [UV], visible, near-infrared, etc.) demonstrating different benefits. Light-emitting diodes (LEDs) offer delivery of light to the skin in a gentler manner as compared to light delivered by lasers, primarily due to the lower energy output. It has been reported that LEDs do not deliver enough power to damage tissues and do not have the same risk of accidental eye damage that lasers do. Visible-LED light therapy has been deemed a non-significant risk by the U.S. Food and Drug Administration (FDA) and has been approved for use in humans.
It is well established in the literature that visible light penetration into the epidermal and dermal layers of human skin is primarily governed by absorption and scattering events, with the latter being the more impactful of the two. Visible light penetration into human skin can be increased by reducing scattering. This can be accomplished by temporary hydrogen bonding disruption, which leads to the reversible rearrangement of epidermal and dermal structures that cause scattering. Glycerol (i.e. glycerin) is hypothesized to generate the level of hydrogen bonding disruption described above, and therefore will be investigated in the present study.
This study will look to evaluate and then compare the acne clearing efficacy and tolerance of two different acne treatment regimens - a cleanser used with a currently marketed red and blue light acne light therapy mask alone vs. the cleanser used with the same mask in conjunction with a light therapy topical gel-cream - to determine the efficacy of these treatments and then to assess if the efficacy of the light therapy mask used with the topical gel-cream treatment is non-inferior to the mask alone in the reduction of lesions in mild to moderate acne. If non-inferiority is demonstrated, the mask with topical gel-cream treatment will be further assessed for its superiority to the mask alone.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
Other names: Light Therapy Mask
A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
Other names: Light Therapy Mask, Light Therapy Topical Gel-Cream
Time frame: Baseline and Week 12
Percent change from baseline in global face total lesion count at Week 12
Time frame: Baseline and Week 2
Percent change from baseline in global face total lesion count at Week 2
Time frame: Baseline and Week 4
Percent change from baseline in global face total lesion count at Week 4
Time frame: Baseline and Week 8
Percent change from baseline in global face total lesion count at Week 8
Time frame: Baseline to Week 2, Week 4, Week 8, and Week 12
Global face total lesion counts are averaged across all applicable post-baseline visits (Week 2, Week 4, Week 8, and Week 12). Percent change from baseline to the mean is then calculated.
Time frame: Baseline to Week 2 and Week 4
Global face total lesion counts are averaged across Week 2 and Week 4. Percent change from baseline to the mean is then calculated.
Time frame: Baseline to Week 4 and Week 8
Global face total lesion counts are averaged across Week 4 and Week 8. Percent change from baseline to the mean is then calculated.
Time frame: Baseline to Week 8 and Week 12
Global face total lesion counts are averaged across Week 8 and Week 12. Percent change from baseline to the mean is then calculated.
Time frame: 2 weeks
Open comedones count on global face - Week 2
Time frame: 4 weeks
Open comedones count on global face - Week 4
Time frame: 8 weeks
Open comedones count on global face - Week 8
Time frame: 12 weeks
Open comedones count on global face - Week 12
Time frame: 2 weeks
Closed comedones count on global face - Week 2
Time frame: 4 weeks
Closed comedones count on global face - Week 4
Time frame: 8 weeks
Closed comedones count on global face - Week 8
Time frame: 12 weeks
Closed comedones count on global face - Week 12
Time frame: 2 weeks
Papules and pustules counted together
Time frame: 4 weeks
Papules and pustules counted together
Time frame: 8 weeks
Papules and pustules counted together
Time frame: 12 weeks
Papules and pustules counted together
Time frame: 2 weeks
Sum of open comedones and closed comedones
Time frame: 4 weeks
Sum of open comedones and closed comedones
Time frame: 8 weeks
Sum of open comedones and closed comedones
Time frame: 12 weeks
Sum of open comedones and closed comedones
Time frame: 2 weeks
Sum of inflammatory and non-inflammatory lesions
Time frame: 4 weeks
Sum of inflammatory and non-inflammatory lesions
Time frame: 8 weeks
Sum of inflammatory and non-inflammatory lesions
Time frame: 12 weeks
Sum of inflammatory and non-inflammatory lesions
Time frame: 1 week
Investigator Global Acne Assessment using Modified Cooke's Scale - Week 1. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.
Time frame: 2 weeks
Investigator Global Acne Assessment using Modified Cooke's Scale - Week 2. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.
Time frame: 4 weeks
Investigator Global Acne Assessment using Modified Cooke's Scale - Week 4. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.
Time frame: 8 weeks
Investigator Global Acne Assessment using Modified Cooke's Scale - Week 8. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.
Time frame: 12 weeks
Investigator Global Acne Assessment using Modified Cooke's Scale - Week 12. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.
Time frame: 1 week
Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness
Time frame: 2 weeks
Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness
Time frame: 4 weeks
Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness
Time frame: 8 weeks
Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness
Time frame: 12 weeks
Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness
Time frame: 1 week
Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large
Time frame: 2 weeks
Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large
Time frame: 4 weeks
Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large
Time frame: 8 weeks
Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large.
Time frame: 12 weeks
Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05080764
Acne Vulgaris, Acneiform Eruptions
Fountain Valley, California, United States
View Trial DetailsNCT07652112
Acne Vulgaris, Acneiform Eruptions
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT06415279
Acne Vulgaris, Acneiform Eruptions
High Point, North Carolina, United States
View Trial DetailsNCT07244887
Acne Vulgaris, Acneiform Eruptions
Istanbul, Turkey (Türkiye)
View Trial Details